Strategic partnerships Leverage Aridis’ HIV bNAb platform and inhaled delivery expertise to identify collaboration opportunities with vaccine developers, global health organizations, and pharma companies seeking novel delivery formats for infectious disease therapies.

Rare asset leverage Target potential buyers or partners for AR-501 nebulized gallium citrate and other inhaled formulations by highlighting CF and chronic lung infection applications, offering co-development or licensing deals to accelerate commercialization.

Clinical optimization Capitalize on past trials and licensing activity (suvratoxumab exit, AstraZeneca collaboration) to approach late-stage programs in infectious diseases with a focus on adjuvanted vaccines and monoclonal antibodies employing Aridis' delivery tech.

Grant and foundation alignment Engage with foundations and public funders (CF Foundation, Gates Foundation) as potential co-development or grant-supported pathways to scale manufacturing and distribution for cost-effective inhaled mAb therapies in LMICs.

Small team agility Position as a nimble partner for mid-size biotech and specialty pharma seeking strategic collaborations to de-risk development, share manufacturing capabilities, or co-fund early-stage programs leveraging Aridis’ ready-to-use formulations.